ELDERLY PATIENTS WITH COVID-19 AND BRONCHIAL ASTHMA
Keywords:
Asthma in the elderly, COVID-19, population, inflammation.Abstract
Bronchial asthma and COVID-19 pose serious health challenges, especially in older patients whose immune system may be weakened and whose comorbidities often complicate the clinical picture. In recent years, there has been an increase in the incidence of both these pathologies, which requires a more detailed study of their relationship. Bronchial asthma, being a chronic inflammatory disease of the airways, can significantly worsen the course of infectious diseases, including COVID-19. Older patients with asthma are at higher risk of developing severe forms of viral infection. Studies show that the presence of asthma increases the likelihood of hospitalization and increased mortality when infected with SARS-CoV-2. This is due to both pathological changes in the lungs and the likelihood of developing comorbidities, such as cardiovascular disorders and diabetes[1]. In addition, COVID-19 itself can provoke an exacerbation of asthma due to viral inflammation and hyperreactivity of the airways. It is important to note that many asthmatics take inhaled corticosteroids, which, according to recent data, may have a protective effect against COVID-19 by reducing inflammation and preventing exacerbations of the disease. [6]However, there is a need for an individualized approach to treatment, taking into account the specifics of each patient. As part of prevention, it is important to vaccinate against COVID-19, which is recommended for older adults with chronic diseases, including asthma, as it has become one of the most effective ways to reduce the risk of serious complications and death. Thus, the management of bronchial asthma in older patients in the context of the COVID-19 pandemic requires an integrated approach, including optimizing treatment, regular health monitoring, and informing patients about risks and precautions. Understanding the relationship between these two conditions will help develop more effective strategies to protect the most vulnerable groups of the population.
References
Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648.
Guan W.J., Liang W.H., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020; 55 (5): 2000547. DOI: 10.1183/13993003.00547- 2020.
Eger K., Bel E.H. Asthma and COVID-19: do we finally have answers? Eur. Respir. J. 2021; 57 (3): 2004451. DOI: 10.1183/13993003.04451- 2020.
Butler M.W., O’Reilly A., Dunican E.M. et al. Prevalence of comorbid asthma in COVID-19 patients. J. Allergy Clin. Immunol. 2020; 146 (2): 334–335. DOI: 10.21037/jtd.2017.08.109.
Choi H.G., Wee J.H., Kim S.Y. et al. Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean disease control and Prevention. Allergy. 2020; 76 (3): 921–924. DOI: 10.1111/all.14675.
Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J. Allergy Clin. Immunol. 2020; 146 (2): 327–329.e4. DOI: 10.1016/j.jaci.2020.06.001.
